Hyperway Pharm Funding: $54M Raised, Series B (2025)
Hyperway Pharm is based in Chengdu, China. It has raised $54M in total funding. Latest round: Series B.
Hyperway Pharm funding overview
Hyperway Pharm is based in Chengdu, China. Hyperway Pharm has raised $54M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in October 2025. The round record for Hyperway Pharm runs through 2025; nothing later has been disclosed. Investors on record include Orinno Capital, Guoyuan Innovating Investment, Sunbow Capital, Hygeia Capital, WAN LEI, Ziyuan Capital and 1 others. 7 distinct backers are named across the disclosed rounds.
Hyperway Pharm at a glance
Total raised
$54M
Latest round
Series B
Latest round date
October 2025
Headquarters
Chengdu, China
Notable investors
Orinno Capital, Guoyuan Innovating Investment, Sunbow Capital, Hygeia Capital, WAN LEI, Ziyuan Capital, Huagai Capital
Frequently asked about Hyperway Pharm funding
How much has Hyperway Pharm raised?
Hyperway Pharm has raised $54M in total disclosed funding across the rounds on record.
Who has invested in Hyperway Pharm?
Orinno Capital, Guoyuan Innovating Investment, Sunbow Capital, Hygeia Capital, WAN LEI, Ziyuan Capital are named among the investors backing Hyperway Pharm.
What was the latest Hyperway Pharm funding round?
The most recent disclosed round is a Series B, announced in October 2025.
Where is Hyperway Pharm based?
Hyperway Pharm is based in Chengdu, China.
When did Hyperway Pharm last raise?
The last disclosed Hyperway Pharm round closed in October 2025 at Series B.
Hyperway Pharm totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Chengdu below to benchmark round size and investor mix.
